We now recognize that patients with meningiomas harboring CDKN2A homozygous deletion or TERT promoter mutation regardless of histologic grade have poor clinical outcomes similar to patients with histologically diagnosed anaplastic (CNS WHO grade 3) meningiomas [10]. This evidence concerns the gene CDKN2A and meningioma.